A Primer on Clinical Classification and Pathophysiology of Endometriosis

Revised American Society for Reproductive Medicine (rASRM)

The American Fertility Society (AFS) proposed the AFS score, a revolutionary technique, in 1979. The endometriosis stage was determined by a cumulative score based on the size of endometriotic lesions in the ovaries, peritoneum and fallopian tubes, as well as the level of adhesion at each of the sites mentioned above. The system was divided into four levels: I (mild to 5 points), II (moderate to 15 points), III (severe to 30 points), and IV (31 to 54 points, extensive).

However, there was no association between the illness stage and the clinical symptoms of pain and infertility in this classification method. As a result, this framework was modified in 1985, and endometriosis was divided into four stages: minimum, mild, moderate, and severe [Figure 3]. The score was divided into four categories: 1–5, 6–15, 16–40 and more than 40. Superficial small, isolated lesions less than 3 cm are classified as minimal, deep infiltrating large lesions greater than 3 cm without adhesions are classified as mild, deep infiltrating lesions greater than 3 cm with filmy adhesions are moderate and deep infiltrating lesions greater than 3 cm with dense adhesions are classified as severe.

Close

Figure 3:

rASRM classification for endometriosis (This figure is modified from the https://www.endometriosis-india.com/classification-of-endometriosis/)

Export to PPT

The rASRM classification has the advantage of being widely used in recent years and being recognised on a global scale. It is very simple to use and useful for professionals when describing the severity of endometriosis to patients.

ENZIAN classification

The commonly used rASRM has some limitations because of its incomplete description of deep endometriosis. In terms of deep infiltrating endometriosis, the ENZIAN classification was designed to complement the rASRM classification rather than to replace it. When this categorisation was used, however, there was an unexpected partial overlap with the rASRM score. Two updates were made in 2010 and 2011 to eliminate the overlay amongst the rASRM classification systems and to make the ENZIAN classification system more user-friendly, as shown in Figure 4.

Close

Figure 4:

The ENZIAN stage system for endometriosis in women. Overview of the ENZIAN categorisation, including compartments and organs that may be impacted (doi: 10.1111/aogs.14099).

Export to PPT

Retroperitoneal structures were categorised into three compartments in the updated classification. The rectovaginal septum and vagina in the posterior region of the uterus comprise compartment A, the uterosacral ligament and pelvic walls comprise compartment B, and the sigmoid colon and rectum comprise compartment C. The invasiveness of the lesion is limited to 1 cm for grade I, 1–3 cm for grade II and more than 3 cm for grade III. The prefix ‘E’ indicates the presence of an endometriosis tumor. The afflicted compartment is designated by the lowercase English letter following the prefix, and the extent of the lesion is indicated by the number following the prefix. Bilateral disease is denoted by two lowercase English letters. Endometriosis can infiltrate local and distant organs in the following ways: ‘FA’ indicates adenomyosis, ‘FB’ for bladder involvement, ‘FU’ for intrinsic ureter involvement, ‘FO’ for other sites and ‘FI’ for intestine involvement.

The ENZIAN classification has the advantage of providing thorough descriptions of the retroperitoneal structures. The compartment can be subdivided into three sections, and each section’s severity can be described, as well as the severity of any remote lesions such as diaphragmatic and ureteral invasions. In addition, the ENZIAN classification can be employed using imaging modalities that are routinely employed for surgical planning. Third, the existence and intensity of various symptoms are related to and correlated with disease localisation and extent. However, there are several drawbacks. First, there is a low level of global acceptance for the ENZIAN categorisation. Second, patients could have trouble interpreting the ENZIAN classification due to the stage’s intricacy and lack of understanding of pelvic anatomy. Third, insufficient surgical dissection of the deep invasive lesions or performing an imaging study just without surgery will result in an incorrect ENZIAN score. Fourth, there are not enough studies to identify whether the ENZIAN categorisation is useful, even if imaging modalities predict it.

Endometriosis Fertility Index (EFI)

While the rASRM and ENZIAN provide an accurate classification of endometriosis, as these reflect disease progression over severity, the classification is inadequate to predict fertility in women with endometriosis. This led to the development of the EFI approach, as shown in Figure 5. This classification offers a definite advantage in terms of pregnancy outcome prediction in women with endometriosis.

Close

Figure 5:

Endometriosis Fertility Index (EFI) system where the number shows the probability that a woman will become pregnant naturally after having endometriosis surgically confirmed (modified from doi: 10.12701/yujm.2020.00444 with permission of Elsevier)

Export to PPT

The EFI approach takes into consideration past events like age, length of infertility and previous pregnancies. The function score is considered by assessing the function of the ovary, fallopian tube and fimbria on each side. The surgeon awards functional scores ranging from 0 to 4 using the following scale: absent or non-functional is assigned a score of 0; severe dysfunction is awarded a score of 1; moderate dysfunction is assigned a score of 2; mild dysfunction is assigned a score of 3, and normal is assigned a score of 4. Along with the least functional score, other surgical factors, such as the rASRM total score and endometriosis lesion score of rASRM, are considered. The EFI score is calculated, which can range from 0 to 10 points, and is determined by summing the historical and surgical values. The higher the EFI score, the greater the probability of fertility. The EFI score effectively represents the pregnancy rate better than the rASRM classification. The EFI score, however, is more difficult to use than the rASRM classification and ENZIAN score since it involves calculating and aggregating the scores of numerous categories.

American Association of Gynaecological Laparoscopists (AAGL)

Compared to the ASRM staging approach, the AAGL 2021 Endometriosis Classification enables the identification of objective intraoperative findings that accurately distinguish surgical complexity levels. The ASRM stage and the AAGL severity stage connect with pain and infertility symptoms equally. This new endometriosis classification was started in 2007 by the AAGL. Thirty endometriosis specialists were asked to rate the importance of the involvement site of the lesion on the outcomes of pain, infertility and surgical difficulty on a scale of 0 to 10. This system included all of the fundamental data deemed necessary for assessing a patient’s disease severity. Furthermore, the classification entails determining the surgical difficulty levels at four levels. Level 1 is the removal of superficial implants and simple thin avascular adhesions; level 2 is the removal of ovarian endometriomas, appendectomy and dense adhesions that do not involve the intestine and ureter; and level 3 is the removal of deep endometriosis that does not involve the vagina, bladder, bowel or ureter. Dense bowel and ureter adhesions, suture-required bladder surgery, ureterolysis and bowel surgery without resection (shaving) are all classified as level 3. Finally, level 4 is assigned when bowel resection with end-to-end anastomosis, ureteral reimplantation or anastomosis is required. Before surgery, the patient’s visual analogue scale scores and infertility histories are recorded to validate the scoring system. Even though it has been more than ten years since the classification was first developed, it has yet to be thoroughly validated and published.

In conclusion, ASRM, ENZIAN and EFI classifications are based on surgical assessment of the disease and its progression, and they meet the fundamental requirements of a clinical classification. The primary drawback of these classifications is their low diagnostic and prognostic use [Supplementary Table 1]. The only exception is the EFI classification, which aids in predicting fertility outcomes.^[12] Recently, it has been proposed that rather than the conventional classification systems, transvaginal ultrasound (TVUS) and MRI-based diagnosis and staging may be better in surgical planning and infertility management in women with endometriosis.^[13,14] However, the data available is insufficient for immediate clinical applications, and more studies from different parts of the world are needed to determine if the imaging-based diagnostic outcomes have any prognostic significance. The need is to create an approach where the classifications/staging systems, symptom assessment and diagnostic imaging are integrated to aid clinicians and patients in predicting the prognosis and determining appropriate treatments. Presently, for classifying this difficult and complex condition, there is still much to learn and to do. To appropriately reflect the severity of symptoms and diseases as well as to choose appropriate treatment options, an ideal categorisation should be devised, but this appears to be far from reality. Till then, clinicians will need to rely on multiple approaches to classify the disease based on the outcomes that are desired.

Treatment

Current treatment for endometriosis is based on surgical/medical therapies or surgical followed by medical therapies. The surgical method includes laparoscopy, which is still the gold standard method for the diagnosis and removal of endometriosis.^[15,16] The purpose of the laparoscopic approach is to destroy or remove all visually evident endometriotic tissues and heal the damage to organs caused by endometriosis, which restores normal anatomy.^[15,17]

Medical therapy for endometriosis is based on the fact that sex steroid hormones modulate the ectopic endometriotic tissue and undergo cyclic changes the same as eutopic endometrium. The main targets are to reduce oestrogen levels (systemically and locally) and to restore pathogenesis-related (PR) resistance. The drugs targeting oestrogen secretion and oestrogen receptor (ER) activity are GnRH-analogues, GnRH antagonists, aromatase inhibitors and selective oestrogen receptor modulators (SERMs). Drugs targeting progesterone or PR activity in the pathogenesis of endometriosis are progestin (oral, intravaginal, intrauterine and subcutaneous) and selective progesterone receptor (PR) modulators.^[3,18] However, available therapies, either surgical or medical, are not appropriate for the long term due to multiple side effects and a high recurrence rate of disease. Therefore, an ideal treatment for endometriosis should be long-standing, have limited side effects, be less painful, balance hormone and receptor levels and improve fertility.^[18]

Genetic predisposition

It is believed that endometriosis has genetic influences that contribute to its pathophysiology. Familial studies, linkage analyses, genetic association studies and genome-wide association studies (GWAS) have provided insight into the pathophysiology of endometriosis via correlating cellular processes to the development of the disease. However, many parts of the disease’s aetiology are still unknown. First-degree relatives of women with severe endometriosis are at six times more risk than relatives of women who are unaffected. Studies on monozygotic twins show significant concordance rates for endometriosis with histological confirmation.^[28] A linkage analysis study covered almost 1100 families and demonstrated that endometriosis is associated with loci on chromosomes 7p13-15 and 10q26.^[29,30] Genetic association studies demonstrated that polymorphism in DNA repair pathway genes (XRCC1, hMLH1), proliferation and differentiation-associated genes (homeobox genes, p27, PLA2G2A, LAMA, KAZN), apoptotic genes (FAS, calpains, KRAS proto-oncogene, SIRT1 and BCL6), tumour suppressor genes (TP53, BCL6, SIRT1), Detoxification genes (CYP genes, GST genes), inflammatory and autoimmunity genes (IL-16, IL-1β, TNF-α, ICAM-1, COX-2, BsrBI, FCRL3), angiogenesis-related genes (FGFR2, VEGF, AKT1, TYMP and other genes), hormonal genes (LH, FSH, ERα) and genes in diverse pathway genes are associated with the risk of developing endometriosis in a different population.^[28]

In a meta-analysis based on GWAS performed in a Japanese female population, four prevalent SNPs were observed near and within the IL1A region, indicating it is a candidate gene.^[31] Four SNPs (rs227849, rs4703908, rs2479037 and rs966674) were also found to be strongly linked with endometrioma risk in a different GWAS that included 2019 diagnosed patients.^[32] The genetic variant rs12700667 on 7p15.2 was found in populations of European and Japanese descent, and a correlation between rs7521902 at 1p36.12 close to WNT4 was confirmed in another GWAS with 4604 patients.^[33] Moreover, another risk locus at 4q12 (rs17773813) was discovered in a GWAS involving 1840 patients of Icelandic descent.^[34]

While the GWAS studies are immensely useful in understanding the genetics of endometriosis, very few of the candidate genes have been experimentally validated to show a functional effect. Thus, these results are considered, at best, associative to explain the genetic predisposition theory of endometriosis.

Oestrogen dependence

Steroid hormones are crucial for preserving endometrial physiology and are thought to be involved in the aetiology of endometriosis. Oestradiol, an oestrogen steroid hormone, is necessary for the development of endometriotic implants.^[35] In addition to oestradiol being produced in the ovary, endometriotic lesions also produce oestradiol locally.^[36,37] The production of oestradiol promotes the synthesis of prostaglandins, which, in turn, drives oestrogen synthesis locally, resulting in a feed-forward system.^[27,38,39]

Oestrogen affects the target tissue by acting on its receptors, namely the ERs, which include the oestrogen receptor alpha (ERα) and oestrogen receptor beta (ERβ). In the normal endometrium, ERα is hormonally controlled and necessary for the proliferation of endometrial cells; ERβ has anti-proliferative and inflammatory functions.^[40–43] Ectopic endometrial tissues overexpress ERβ, which causes ERα to be suppressed and reduces ERα-mediated activation of the PR. This altered ERα/ERβ favours cell survival, maintains inflammation, and may contribute to progesterone resistance.^[2]

Progesterone resistance

In its natural state, progesterone causes the endometrium to decidualise, inhibits oestrogen-dependent endometrial growth and serves as an anti-inflammatory.^[44,45] Progesterone resistance in endometriosis was hypothesised as a result of in vitro experiments that revealed progesterone was unable to trigger the formation of retinoic acid in endometriosis lesions.^[46,47] Since retinoic acid is not produced, endometriotic lesions have higher than normal levels of oestradiol, which promotes further growth.^[48,49] In addition, endometriosis has a low PR isoform B (PR-B) to PR isoform A (PR-A) ratio. PR-B is a powerful transactivator in response to progesterone, and PR-A is a dominant repressor,^[50] but it is possible that reduced PR-B is a contributing factor in progesterone resistance.^[46,51–53].

Beyond the expression of the receptors, endometrial gene expression analysis has revealed that endometriosis-affected women have reduced expression of progesterone target genes during the window of embryo implantation.^[54,55] These genes play a role in immunomodulation and decidualisation, indicating that the eutopic endometrium of women with endometriosis is also progesterone-resistant.^[51,53] In the normal endometrium, HOXA10 is a direct target of PR in endometrial stromal cells and drives the expression of many progesterone-regulated genes.^[56,57] The expression of HOXA10 is also reduced in the eutopic and ectopic endometrium of women with endometriosis. Epigenetic modifications also have a role in progesterone resistance.^[58,59] Studies have demonstrated that the promoter of the PRB gene, HOXA10, DNMTs (DNA methyltransferases) and steroidogenic factor-1 (SF-1) are hypermethylated in eutopic endometrium.^[46,60] Furthermore, endometriosis tissues have hypomethylation of ERβ, which may be a reason for the increased expression of ERβ.^[46,61]

At present, it appears that the acquisition of oestrogen dominance and progesterone resistance could be a possible reason for the development of endometriotic lesions at ectopic locations. Indeed, we and others have shown experimentally that oestrogen is necessary for the development of endometriotic lesions in mouse models^[62,63]; mice lacking ER isoforms do not effectively develop endometriosis.^[64,65]

Inflammation

A key characteristic of endometriosis is inflammation; however, it is unknown whether this condition contributes to the onset of the disease or is responsible for its progression. The interaction between immune and hormonal systems significantly influences the pathogenesis and development of endometriosis. E2 has a notable function in the promotion of inflammation by inducing the release of cytokines and prostaglandins from peritoneal macrophages^[66] by the action of ERβ.^[67] ERα has a dual role, with both anti- and proinflammatory actions.^[63] However, there is an imbalance in the sex steroid hormones’ actions in endometriosis, with oestrogens playing a significant part in the condition’s exaggerated proinflammatory state.

In endometriosis, cytokine concentrations are abnormally elevated. Multiple studies have revealed elevated levels of TNF-α, IL-1β, IL-6, IL-8, CCL2, CCL5 and VEGF in affected patients.^[68–73] The nuclear factor kappa-light-chain-enhancer of activated B cells is activated by this influx of proinflammatory cytokines, which intensifies the inflammatory response and counteracts the benefits of progesterone.^[74] It has also been noted that immune cell distribution is aberrant. Peritoneal fluid lymphocyte numbers are higher even when the total number of lymphocytes in the blood is unchanged.^[75,76] Additionally, there is an increase in peritoneal macrophage concentrations, which paradoxically drive endometriotic lesions by promoting angiogenesis.^[77–80]. The reduced cytotoxicity of natural killer cells may also improve lesion survival.^[80–83] Furthermore, it is observed that the sera of the diseased women include antibodies to ovarian and endometrial antigens.^[84–86] These findings imply that endometriosis is associated with autoimmune disorders. This association is further supported by a meta-analysis showing a statistically significant correlation between endometriosis and at least one classic autoimmune disease, including Systemic Lupus Erythematosus (SLE), Sjögren’s Syndrome (SS), Rheumatoid Arthritis (RA), Autoimmune Thyroid Disorder, Coeliac Disease (CLD), Multiple Sclerosis (MS), and Inflammatory Bowel Disease (IBD).

Thus, it appears that endometriosis has a broad inflammatory environment that extends outside the pelvis and is marked by the presence of proinflammatory cytokines and changes in the populations of circulating immune cells. Intriguingly, an association of polymorphisms in inflammation-related genes is also reported.^[87–89] Thus, genetic predisposition and the creation of an inflammatory milieu due to oestrogen dominance and progesterone resistance may contribute to endometriosis.